EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Computational Advances in Simulating PCSK9 Variant Dynamics for Therapeutic Design Against Hypercholesterolemia

Ma Cecilia Opazo, Andrés Gallegos, Antar Muñoz, Roger Zapata iD, Juan Carlos Rivera, Romina V Sepúlveda iD, Daniel Aguayo iD

International Journal of Molecular Sciences · 29.10.2026 · 27 (21) · 9676

DOI: 10.3390/ijms27219676 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.10.2026. Verfasst von Ma Cecilia Opazo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Medicina Veterinaria y Agronomía, Instituto de Ciencias Naturales, Universidad de Las Américas, Santiago 7500975, Chile. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Hypercholesterolemia, Computational Biology. Die Arbeit nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Andrés Bello University, Fondo Nacional de Desarrollo Científico y Tecnológico, Millennium Science Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a premier model for precision medicine, having moved from genetic discovery to approved therapeutics within two decades. Yet despite the clinical success of monoclonal antibodies, small interfering RNA and the newly approved oral macrocyclic-peptide inhibitor class, targeting PCSK9 remains a demanding biophysical challenge. Clinical translation has concentrated almost entirely on the rigid, well-resolved subtilisin-like catalytic domain that interfaces with the low-density lipoprotein receptor (LDLR). By contrast, the C-terminal cysteine- and histidine-rich domain (CHRD), which governs allosteric regulation, protein trafficking and post-translational modification, is highly disordered and largely elusive in experimental structures, leaving a critical regulatory network therapeutically unexploited. This review examines how advanced computational biology is bridging that structural gap, organizing the computational landscape of PCSK9 around the biophysical mechanisms of gain- and loss-of-function variants. We detail how explicit-solvent molecular dynamics, free-energy calculations and cryptic-pocket detection expose the functional plasticity and allosteric networks that static crystallography cannot capture, and we evaluate the convergence of these physics-based approaches with artificial intelligence, including deep-learning structure prediction and generative design of de novo nanobody and peptide binders. Therapeutic development and the structural literature currently point in diverging directions: drug discovery remains focused on the crowded LDLR-binding interface, whereas computational methods are beginning to identify candidate sites beyond it. We argue that the next advance in PCSK9 therapeutics will come from integrating generative artificial intelligence with rigorous enhanced sampling in a unified pipeline, deliberately shifting focus toward the disordered regulatory domains that have evaded classical screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proprotein Convertase 9HypercholesterolemiaComputational BiologyHumansMolecular Dynamics SimulationDrug Design

Stichwörter der Autor:innen

PCSK9cysteine-histidine-rich domain (CHRD)gain-of-function and loss-of-function variantsgenerative protein designmolecular dynamics simulation

Substanzen

Proprotein Convertase 9PCSK9 protein, human

Autor:innen und Institutionen

  • Facultad de Medicina Veterinaria y Agronomía, Instituto de Ciencias Naturales, Universidad de Las Américas, Santiago 7500975, Chile.
  • Centro de Investigación en Ciencias Biológicas y Químicas, Universidad de Las Américas, Santiago 7500975, Chile.
  • Programa de Magister en Ciencias Biológicas y Químicas, Facultad de Medicina Veterinaria y Agronomía, Instituto de Ciencias Naturales, Universidad de las Américas, Santiago 7500000, Chile.
  • Departamento de Ciencias de la Ingeniería, Facultad de Ingeniería, Universidad Andrés Bello, Santiago 8370146, Chile.
  • Institute for Advanced Biomedical Research, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.
  • Center for Bioinformatics and Integrative Biology (CBIB), Facultad de Ciencias de La Vida, Universidad Andres Bello, Santiago 8370146, Chile.

ORCID-Profile: Roger Zapata, Romina V Sepúlveda, Daniel Aguayo

Förderung

  • Andrés Bello University
  • Fondo Nacional de Desarrollo Científico y Tecnológico
  • Millennium Science Initiative

Zitieren

APA

Opazo, M. C., Gallegos, A., Muñoz, A., Zapata, R., Rivera, J. C., Sepúlveda, R. V., & Aguayo, D. (2026). Emerging Computational Advances in Simulating PCSK9 Variant Dynamics for Therapeutic Design Against Hypercholesterolemia. International Journal of Molecular Sciences, 27(21), 9676. https://doi.org/10.3390/ijms27219676

Vancouver

Opazo MC, Gallegos A, Muñoz A, Zapata R, Rivera JC, Sepúlveda RV, et al. Emerging Computational Advances in Simulating PCSK9 Variant Dynamics for Therapeutic Design Against Hypercholesterolemia. International Journal of Molecular Sciences. 2026;27(21):9676. doi:10.3390/ijms27219676

BibTeX
@article{Opazo2026,
  author = {Opazo, Ma Cecilia and Gallegos, Andrés and Muñoz, Antar and Zapata, Roger and Rivera, Juan Carlos and Sepúlveda, Romina V and Aguayo, Daniel},
  title = {Emerging Computational Advances in Simulating PCSK9 Variant Dynamics for Therapeutic Design Against Hypercholesterolemia},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {9676},
  doi = {10.3390/ijms27219676}
}
Kostenlos starten →